Jevtana, Zytiga and Xtandi to push prostate cancer market to new heights
This article was originally published in Scrip
A recent influx of novel drugs to treat metastatic castration-resistant prostate cancer (mCRPC) will help drive strong growth in this market over the next ten years, a new forecast from Datamonitor has found.
You may also be interested in...
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.